肝衰竭相关病因对临床结局的预测价值
该研究收集2020年1—12月无锡市第五人民医院ICU收治的112例HBV相关和非HBV相关肝衰竭患者临床数据,分析各亚型病因构成及人工肝支持系统疗效,采用Spearman相关分析、多因素Logistic回归和ROC曲线评估预后预测价值。结果显示,HBV肝衰竭组男性为女性的6倍,高于非HBV肝衰竭组的1.33倍;非HBV肝衰竭组中AT III对预后有预测价值,AUC=0.747(95%CI 0.592-0.902,P=0.009),最佳截断值39.5%时敏感度83.33%、特异度56.25%。多因素分析显示AT III是非HBV肝衰竭预后的独立危险因素(OR=1.023,95%CI -0.001至0.001,P=0.007),TBil是HBV肝衰竭预后的独立危险因素(OR=1.005,95%CI -0.002至-7.543,P=0.033)。作者认为,人工肝支持系统治疗肝衰竭难以有效降低终末期肝衰竭患者病死率;除AT III外,TBil也可作为评估肝衰竭患者肝脏代偿能力和预测预后的指标。
要点
- 非HBV肝衰竭组AT III对预后有预测价值:AUC=0.747(95%CI 0.592-0.902,P=0.009),最佳截断值39.5%时敏感度83.33%、特异度56.25%。
- 多因素Logistic回归显示AT III是非HBV肝衰竭预后的独立危险因素(OR=1.023,95%CI -0.001至0.001,P=0.007)。
- 多因素Logistic回归显示TBil是HBV肝衰竭预后的独立危险因素(OR=1.005,95%CI -0.002至-7.543,P=0.033)。
- 两组存活患者AT III水平均显著高于死亡患者:HBV肝衰竭组(36.20±6.26)% vs.(27.33±8.87)%,非HBV肝衰竭组(41.06±4.16)% vs.(28.71±12.35)%,均P<0.01。
- 使用人工肝支持系统的病死率在HBV肝衰竭组与非HBV肝衰竭组间无统计学显著差异(55.6% vs. 50.0%,P<0.05)。
适用人群与场景
- 2020年1—12月无锡市第五人民医院ICU收治的112例HBV相关和非HBV相关肝衰竭患者,其中HBV相关63例、非HBV相关49例。
诊断标准与关键阈值
- 肝衰竭分为急性、亚急性、慢加急性、慢加亚急性、慢性亚型。
- 非HBV肝衰竭组AT III预测预后的最佳截断值为39.5%,敏感度83.33%、特异度56.25%。
研究设计与关键结果
- HBV肝衰竭组男性为女性的6倍,高于非HBV肝衰竭组的1.33倍。
- HBV肝衰竭组中亚急性肝衰竭AT III和TBil水平高于肝衰竭前期[AT III:(59.33±14.57)% vs.(35.66±20.72)%,TBil(μmol/L):399.21±112.94 vs. 206.08±126.96,均P<0.05]。
- 非HBV肝衰竭组中肝衰竭前期和慢性肝衰竭患者AT III水平显著高于急性肝衰竭[(58.33±15.28)%、(44.00±19.10)% vs.(31.33±7.57)%,均P<0.05]。
- 非HBV肝衰竭组中急性肝衰竭患者TBil显著低于肝衰竭前期(μmol/L:107.83±49.73 vs. 286.20±128.92,P<0.05);亚急性和慢加急性肝衰竭患者TBil也显著高于肝衰竭前期(μmol/L:417.27±118.60、373.00±187.00 vs. 286.20±128.92,均P<0.05)。
- 非HBV肝衰竭组中亚急性肝衰竭、慢加亚急性肝衰竭和慢性肝衰竭患者的住院时间显著长于急性肝衰竭(天:36.00±8.31、27.52±11.71、27.72±22.71 vs. 11.00±1.41,均P<0.05)。
- 使用人工肝支持系统的病死率在HBV肝衰竭组与非HBV肝衰竭组间无统计学显著差异(55.6% vs. 50.0%,P<0.05)。
- 两组存活患者AT III水平均显著高于死亡患者[HBV肝衰竭组:(36.20±6.26)% vs.(27.33±8.87)%,非HBV肝衰竭组:(41.06±4.16)% vs.(28.71±12.35)%,均P<0.01]。
- Spearman相关分析显示,HBV肝衰竭组死亡患者及非HBV肝衰竭组存活和死亡患者中AT III与TBil呈正相关(r值分别为0.069、0.341、0.064,P值分别为0.723、1.196、0.761);HBV肝衰竭组中AT III与TBil呈显著负相关(r=-0.105,P=0.745)。
证据类型、等级与局限
- 证据类型:单中心临床数据回顾性分析(2020年1—12月无锡市第五人民医院ICU收治的112例肝衰竭患者)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,人工肝支持系统治疗肝衰竭难以有效降低终末期肝衰竭患者病死率。
- 作者认为,除AT III外,TBil也可作为评估肝衰竭患者肝脏代偿能力和预测预后的指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the predictors of outcomes for different subtypes of liver failure, and the effectiveness of artificial liver support systems in the treatment of liver failure.
METHODS: The clinical data of 112 patients with hepatitis B virus (HBV)- and non-HBV-related liver failure admitted to the intensive care unit (ICU) of the Fifth People's Hospital of Wuxi were collected from January to December 2020. The relevant etiologies of acute, subacute, acute-on-chronic, subacute-on-chronic, chronic subtype liver failure were analyzed. The efficacies of artificial liver support systems in the treatment of various subtypes of liver failure were also compared. The correlation of various indicators was analyzed by Spearman correlation analysis, the risk factors affecting the prognosis of patients with liver failure were analyzed by multivariate Logistic regression equation, and receiver operator characteristic curve (ROC curve) of subjects was plotted to evaluate the predictive value of each risk factor for the prognosis of patients with liver failure.
RESULTS: Among the 112 liver failure patients, 63 were caused by hepatitis B and 49 were caused by non-hepatitis B. The liver failure caused by hepatitis B was 6 times higher than for men than for women, which was higher than that of non-HBV liver failure group (1.33 times). Antithrombin III (AT III) and total bilirubin (TBil) levels of subacute liver failure were higher than those of pre-liver failure in the HBV liver failure group [AT III: (59.33±14.57)% vs. (35.66±20.72)%, TBil (μmol/L): 399.21±112.94 vs. 206.08±126.96, both P < 0.05]. The levels of AT III in patients with pre-liver failure and chronic liver failure in the non-HBV liver failure group were significantly higher than those with acute liver failure [(58.33±15.28)%, (44.00±19.10)% vs. (31.33±7.57)%, both P < 0.05], patients with acute liver failure had significantly lower level of TBil than pre-liver failure (μmol/L: 107.83±49.73 vs. 286.20±128.92, P < 0.05), the TBil levels in patients with subacute and acute-on-chronic liver failure were also significantly higher than that in pre-liver failure group (μmol/L: 417.27±118.60, 373.00±187.00 vs. 286.20±128.92, both P < 0.05). Patients with subacute liver failure, subacute-on-chronic liver failure and chronic liver failure in the non-HBV failure group were significantly longer than those in acute liver failure (days: 36.00±8.31, 27.52±11.71, 27.72±22.71 vs. 11.00±1.41, all P < 0.05). There was no statistically significant difference in the case fatality rate of using the artificial liver support system between the HBV failure group and the non-HBV failure group (55.6% vs. 50.0%, P < 0.05), the levels of AT III in the two groups of surviving patients were significantly higher than that of the dead [HBV liver failure group: (36.20±6.26)% vs. (27.33±8.87)%, non-HBV liver failure group: (41.06±4.16)% vs. (28.71±12.35)%, both P < 0.01]. Correlation analysis showed that there was a clear positive correlation between AT III and TBil in the dead patients of HBV liver failure group and the survival and death patients of non-HBV liver failure group (r values were 0.069, 0.341, 0.064, and P values were 0.723, 1.196 and 0.761, respectively); there was a significant inverse correlation between AT III and TBil in the HBV liver failure group (r = -0.105, P = 0.745). Multivariate Logistic regression analysis showed that AT III was an independent risk factor affecting the prognosis of patients with non-HBV liver failure [odd ratio (OR) = 1.023, 95% confidence interval (95%CI) was -0.001 to 0.001, P = 0.007]. TBil was an independent risk factor affecting prognosis of patients with HBV liver failure (OR = 1.005, 95%CI was -0.002 to -7.543, P = 0.033). The analysis of ROC curve showed that AT III had a predictive value for the prognosis of patients with non-HBV liver failure, the area under the ROC curve (AUC) = 0.747, the 95%CI was 0.592-0.902, P = 0.009. When the optimal truncation value was 39.5%, its sensitivity and specificity were 83.33% and 56.25%, respectively.
CONCLUSIONS: Artificial liver support system treatment of liver failure was difficult to effectively reduce the mortality of patients with end-stage liver failure. In addition to AT III, TBil also could be used as an indicator to assess liver compensatency and predict prognosis in liver failure patients.
参考来源
- Yan Y, Lyu C, Zhou X, et al. [The predictive value of liver failure-related etiology for clinical outcomes]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35387724. doi:10.3760/cma.j.cn121430-20210705-01006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。